biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by Cdn_clipperon Apr 22, 2016 8:24am

134 Views

Post# 24797832

RE:RE:Licensing Deal - Very Little Detail - Astellas Research

If material, the impacts will eventually be visible in their quarterly financial statements. Astella is ranked 21st amongst global pharma companies. Maybe not a household name, but ranks 77th in global R&D expenditures. Rather pleasing development; certainly can't hurt and maybe there will be a few more licensing agreements in the next 6 months. CC

Bullboard Posts

Avicanna announces medical cannabis study through MyMedi.ca